These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 9492818)
1. [Development of an anticancer drug in Japan based on a new clinical trial system]. Nakashima H; Nakano S Gan To Kagaku Ryoho; 1998 Feb; 25(3):287-94. PubMed ID: 9492818 [TBL] [Abstract][Full Text] [Related]
2. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry]. Ebi O Gan To Kagaku Ryoho; 1997 Oct; 24(13):1883-91. PubMed ID: 9350232 [TBL] [Abstract][Full Text] [Related]
3. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer]. Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963 [TBL] [Abstract][Full Text] [Related]
4. [Roles of nurses in clinical trials of anticancer drug development]. Matsuura C Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):231-4. PubMed ID: 9987524 [TBL] [Abstract][Full Text] [Related]
5. [Doctor-initiated clinical trials and the revised pharmaceutical affairs law]. Takano T; Saijo N Gan To Kagaku Ryoho; 2003 Oct; 30(10):1391-7. PubMed ID: 14584270 [TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
7. [Participation to international registration trials--from the investigator's standpoint]. Ohtsu A Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548 [TBL] [Abstract][Full Text] [Related]
8. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan. Forster MD; Saijo N; Seymour L; Calvert H Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555 [TBL] [Abstract][Full Text] [Related]
9. [ICH-GCP Guideline: quality assurance of clinical trials. Status and perspectives]. Englev E; Petersen KP Ugeskr Laeger; 2003 Apr; 165(16):1659-62. PubMed ID: 12756823 [TBL] [Abstract][Full Text] [Related]
10. [Consideration of clinical development for new anticancer drugs on Japan, proposal from approval reviewer]. Urano T Gan To Kagaku Ryoho; 2007 Feb; 34(2):305-7. PubMed ID: 17301550 [TBL] [Abstract][Full Text] [Related]
11. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise]. Ekimoto H Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236 [TBL] [Abstract][Full Text] [Related]
12. [Globalization of clinical trials]. Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692 [TBL] [Abstract][Full Text] [Related]
13. [Need to establish academic research organization for cancer clinical trial and clinical research system having clinical investigators and study coordinators, with special reference to promotion of medical and life science research policy]. Shimoyama M Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):235-46. PubMed ID: 9987525 [TBL] [Abstract][Full Text] [Related]
14. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan]. Pflieger M; Bertram D Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054 [TBL] [Abstract][Full Text] [Related]
15. Recent changes in quality in Japanese clinical trials. Saito K; Kodama Y; Ono S; Fujimura A Ann Pharmacother; 2004 Jan; 38(1):151-5. PubMed ID: 14742810 [TBL] [Abstract][Full Text] [Related]
16. [Experience as a model hospital for new good clinical practice (GCP) regulations]. Tanaka S Gan To Kagaku Ryoho; 1998 Aug; 25(10):1467-73. PubMed ID: 9725036 [TBL] [Abstract][Full Text] [Related]
17. [The role of the Danish Medical Products Agency in clinical trials]. Simonsen AC Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821 [TBL] [Abstract][Full Text] [Related]
19. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency. Netzer T Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598 [TBL] [Abstract][Full Text] [Related]
20. [Introduction of new GCP (good clinical practice)]. Miyake S Gan To Kagaku Ryoho; 1998 Apr; 25(5):645-9. PubMed ID: 9571961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]